US 12,435,072 B2
Compounds
Tomas Fex, Mölndal (SE); and Bengt Ohlsson, Mölndal (SE)
Assigned to Vicore Pharma AB, Stockholm (SE)
Appl. No. 17/761,670
Filed by Vicore Pharma AB, Stockholm (SE)
PCT Filed Sep. 18, 2020, PCT No. PCT/GB2020/052261
§ 371(c)(1), (2) Date Mar. 18, 2022,
PCT Pub. No. WO2021/053344, PCT Pub. Date Mar. 25, 2021.
Claims priority of application No. 1913603 (GB), filed on Sep. 20, 2019.
Prior Publication US 2022/0388994 A1, Dec. 8, 2022
Int. Cl. C07D 409/10 (2006.01); C07D 409/14 (2006.01)
CPC C07D 409/10 (2013.01) [C07D 409/14 (2013.01)] 18 Claims
 
1. A compound of formula I,
wherein:

OG Complex Work Unit Chemistry
R1 represents C1-6 alkyl, optionally substituted by one or more halogen atoms;
R2 and R3 independently represent H or C1-6 alkyl, optionally substituted by one or more halogen atoms;
Y1, Y2, Y3 and Y4 independently represent —CH—, —CF— or —N—;
R4 represents C1-7 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, each of which are optionally substituted with one or more halogen atoms, or
R4 represents aryl, C1-6 alkylaryl, C1-3 alkenylaryl, heteroaryl, C1-6 alkylheteroaryl or C1-3 alkenylheteroaryl, each of which are optionally substituted by one or more substituents selected from halogen, CF3, CF3O, C1-6 alkyl, and C1-6 alkoxy;
R5 represents H or C1-6 alkyl, optionally substituted by one or more halogen atoms; and
R6 represents C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, each of which are optionally substituted by one or more halogen atoms,
or a pharmaceutically-acceptable salt thereof.